Among the main studies about DOACs, only ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) and ENGAGE AF (effective anticoagulation with factor Xa next generation in atrial fibrillation) included patients with bioprosthesis or valve repair and AF. Here, F10 is linked to stroke disorder.